Summary
Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
According to APO Research, The global Alpha 1 Antitrypsin Deficiency Treatment market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Alpha 1 Antitrypsin Deficiency Treatment is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Alpha 1 Antitrypsin Deficiency Treatment is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Alpha 1 Antitrypsin Deficiency Treatment is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Alpha 1 Antitrypsin Deficiency Treatment is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Alpha 1 Antitrypsin Deficiency Treatment include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols and CSL Behring, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Alpha 1 Antitrypsin Deficiency Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Alpha 1 Antitrypsin Deficiency Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Alpha 1 Antitrypsin Deficiency Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Alpha 1 Antitrypsin Deficiency Treatment revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Alpha 1 Antitrypsin Deficiency Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Alpha 1 Antitrypsin Deficiency Treatment revenue, projected growth trends, production technology, application and end-user industry.
Alpha 1 Antitrypsin Deficiency Treatment segment by Company
Pfizer
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical Industries
Takeda
Baxter
Grifols
CSL Behring
Kamada Ltd
Chiesi Pharmaceuticals
Kedrion Group
Vertex Pharmaceuticals
ProMetic Life Sciences
Alpha 1 Antitrypsin Deficiency Treatment segment by Indication
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes
Other
Alpha 1 Antitrypsin Deficiency Treatment segment by End Users
COPD
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes
Alpha 1 Antitrypsin Deficiency Treatment segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alpha 1 Antitrypsin Deficiency Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Alpha 1 Antitrypsin Deficiency Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alpha 1 Antitrypsin Deficiency Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Alpha 1 Antitrypsin Deficiency Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Alpha 1 Antitrypsin Deficiency Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Alpha 1 Antitrypsin Deficiency Treatment revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
1 Market Overview
1.1 Product Definition
1.2 Alpha 1 Antitrypsin Deficiency Treatment Market by Indication
1.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication, 2019 VS 2023 VS 2030
1.2.2 Augmentation Therapy
1.2.3 Cystic Fibrosis(CF)
1.2.4 Non-CF Bronchiectasis(NCFB)
1.2.5 Diabetes
1.2.6 Other
1.3 Alpha 1 Antitrypsin Deficiency Treatment Market by End Users
1.3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users, 2019 VS 2023 VS 2030
1.3.2 COPD
1.3.3 Cystic Fibrosis(CF)
1.3.4 Non-CF Bronchiectasis(NCFB)
1.3.5 Diabetes
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics
2.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends
2.2 Alpha 1 Antitrypsin Deficiency Treatment Industry Drivers
2.3 Alpha 1 Antitrypsin Deficiency Treatment Industry Opportunities and Challenges
2.4 Alpha 1 Antitrypsin Deficiency Treatment Industry Restraints
3 Global Growth Perspective
3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Perspective (2019-2030)
3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Growth Trends by Region
3.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2019-2024)
3.2.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2025-2030)
4 Competitive Landscape by Players
4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players
4.1.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players (2019-2024)
4.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players (2019-2024)
4.1.3 Global Alpha 1 Antitrypsin Deficiency Treatment Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Alpha 1 Antitrypsin Deficiency Treatment Key Players Headquarters & Area Served
4.4 Global Alpha 1 Antitrypsin Deficiency Treatment Players, Product Type & Application
4.5 Global Alpha 1 Antitrypsin Deficiency Treatment Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market CR5 and HHI
4.6.2 Global Top 5 and 10 Alpha 1 Antitrypsin Deficiency Treatment Players Market Share by Revenue in 2023
4.6.3 2023 Alpha 1 Antitrypsin Deficiency Treatment Tier 1, Tier 2, and Tier 3
5 Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type
5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2019-2030)
5.3 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Type (2019-2030)
6 Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application
6.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2019-2030)
6.3 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Application (2019-2030)
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Comapny Information
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2019-2024)
7.1.4 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
7.1.5 Pfizer Recent Developments
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Comapny Information
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2019-2024)
7.2.4 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
7.2.5 GlaxoSmithKline Recent Developments
7.3 AstraZeneca
7.3.1 AstraZeneca Comapny Information
7.3.2 AstraZeneca Business Overview
7.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2019-2024)
7.3.4 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
7.3.5 AstraZeneca Recent Developments
7.4 Boehringer Ingelheim
7.4.1 Boehringer Ingelheim Comapny Information
7.4.2 Boehringer Ingelheim Business Overview
7.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2019-2024)
7.4.4 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
7.4.5 Boehringer Ingelheim Recent Developments
7.5 Teva Pharmaceutical Industries
7.5.1 Teva Pharmaceutical Industries Comapny Information
7.5.2 Teva Pharmaceutical Industries Business Overview
7.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2019-2024)
7.5.4 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
7.5.5 Teva Pharmaceutical Industries Recent Developments
7.6 Takeda
7.6.1 Takeda Comapny Information
7.6.2 Takeda Business Overview
7.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2019-2024)
7.6.4 Takeda Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
7.6.5 Takeda Recent Developments
7.7 Baxter
7.7.1 Baxter Comapny Information
7.7.2 Baxter Business Overview
7.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2019-2024)
7.7.4 Baxter Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
7.7.5 Baxter Recent Developments
7.8 Grifols
7.8.1 Grifols Comapny Information
7.8.2 Grifols Business Overview
7.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2019-2024)
7.8.4 Grifols Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
7.8.5 Grifols Recent Developments
7.9 CSL Behring
7.9.1 CSL Behring Comapny Information
7.9.2 CSL Behring Business Overview
7.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2019-2024)
7.9.4 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
7.9.5 CSL Behring Recent Developments
7.10 Kamada Ltd
7.10.1 Kamada Ltd Comapny Information
7.10.2 Kamada Ltd Business Overview
7.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2019-2024)
7.10.4 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
7.10.5 Kamada Ltd Recent Developments
7.11 Chiesi Pharmaceuticals
7.11.1 Chiesi Pharmaceuticals Comapny Information
7.11.2 Chiesi Pharmaceuticals Business Overview
7.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2019-2024)
7.11.4 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
7.11.5 Chiesi Pharmaceuticals Recent Developments
7.12 Kedrion Group
7.12.1 Kedrion Group Comapny Information
7.12.2 Kedrion Group Business Overview
7.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2019-2024)
7.12.4 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
7.12.5 Kedrion Group Recent Developments
7.13 Vertex Pharmaceuticals
7.13.1 Vertex Pharmaceuticals Comapny Information
7.13.2 Vertex Pharmaceuticals Business Overview
7.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2019-2024)
7.13.4 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
7.13.5 Vertex Pharmaceuticals Recent Developments
7.14 ProMetic Life Sciences
7.14.1 ProMetic Life Sciences Comapny Information
7.14.2 ProMetic Life Sciences Business Overview
7.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2019-2024)
7.14.4 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
7.14.5 ProMetic Life Sciences Recent Developments
8 North America
8.1 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue (2019-2030)
8.2 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2019-2030)
8.2.1 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2019-2024)
8.2.2 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2025-2030)
8.3 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Indication (2019-2030)
8.4 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2019-2030)
8.4.1 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2019-2024)
8.4.2 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2025-2030)
8.5 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by End Users (2019-2030)
8.6 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country
8.6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2019-2024)
8.6.3 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2025-2030)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue (2019-2030)
9.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2019-2030)
9.2.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2019-2024)
9.2.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2025-2030)
9.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Indication (2019-2030)
9.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2019-2030)
9.4.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2019-2024)
9.4.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2025-2030)
9.5 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by End Users (2019-2030)
9.6 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country
9.6.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2019-2024)
9.6.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 China
10.1 China Alpha 1 Antitrypsin Deficiency Treatment Revenue (2019-2030)
10.2 China Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2019-2030)
10.2.1 China Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2019-2024)
10.2.2 China Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2025-2030)
10.3 China Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Indication (2019-2030)
10.4 China Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2019-2030)
10.4.1 China Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2019-2024)
10.4.2 China Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2025-2030)
10.5 China Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by End Users (2019-2030)
11 Asia (Excluding China)
11.1 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue (2019-2030)
11.2 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2019-2030)
11.2.1 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2019-2024)
11.2.2 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2025-2030)
11.3 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Indication (2019-2030)
11.4 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2019-2030)
11.4.1 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2019-2024)
11.4.2 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2025-2030)
11.5 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by End Users (2019-2030)
11.6 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country
11.6.1 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2019-2024)
11.6.3 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 Middle East, Africa, Latin America
12.1 MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue (2019-2030)
12.2 MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2019-2030)
12.2.1 MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2019-2024)
12.2.2 MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2025-2030)
12.3 MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Indication (2019-2030)
12.4 MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2019-2030)
12.4.1 MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2019-2024)
12.4.2 MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2025-2030)
12.5 MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by End Users (2019-2030)
12.6 MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country
12.6.1 MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2019-2024)
12.6.3 MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
List of Tables
Table 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Indication (US$ Million), 2019 VS 2023 VS 2030
Table 1. Augmentation Therapy Major Manufacturers
Table 2. Cystic Fibrosis(CF) Major Manufacturers
Table 3. Non-CF Bronchiectasis(NCFB) Major Manufacturers
Table 4. Diabetes Major Manufacturers
Table 5. Other Major Manufacturers
Table 6. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by End Users (US$ Million), 2019 VS 2023 VS 2030
Table 7. COPD Major Manufacturers
Table 8. Cystic Fibrosis(CF) Major Manufacturers
Table 9. Non-CF Bronchiectasis(NCFB) Major Manufacturers
Table 10. Diabetes Major Manufacturers
Table 11. Alpha 1 Antitrypsin Deficiency Treatment Industry Trends
Table 12. Alpha 1 Antitrypsin Deficiency Treatment Industry Drivers
Table 13. Alpha 1 Antitrypsin Deficiency Treatment Industry Opportunities and Challenges
Table 14. Alpha 1 Antitrypsin Deficiency Treatment Industry Restraints
Table 15. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 16. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 17. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2019-2024)
Table 18. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2025-2030) & (US$ Million)
Table 19. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2025-2030)
Table 20. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players (US$ Million) & (2019-2024)
Table 21. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players (2019-2024)
Table 22. Global Alpha 1 Antitrypsin Deficiency Treatment Key Players Ranking, 2022 VS 2023 VS 2024
Table 23. Global Alpha 1 Antitrypsin Deficiency Treatment Key Players Headquarters & Area Served
Table 24. Global Alpha 1 Antitrypsin Deficiency Treatment Players, Product Type & Application
Table 25. Global Alpha 1 Antitrypsin Deficiency Treatment Players Commercialization Time
Table 26. Global Players Market Concentration Ratio (CR5 and HHI)
Table 27. Global Alpha 1 Antitrypsin Deficiency Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 28. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2019-2024) & (US$ Million)
Table 30. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2025-2030) & (US$ Million)
Table 31. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2019-2024) & (US$ Million)
Table 32. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2025-2030) & (US$ Million)
Table 33. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users 2019 VS 2023 VS 2030 (US$ Million)
Table 34. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2019-2024) & (US$ Million)
Table 35. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2025-2030) & (US$ Million)
Table 36. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2019-2024) & (US$ Million)
Table 37. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2025-2030) & (US$ Million)
Table 38. Pfizer Company Information
Table 39. Pfizer Business Overview
Table 40. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 41. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
Table 42. Pfizer Recent Development
Table 43. GlaxoSmithKline Company Information
Table 44. GlaxoSmithKline Business Overview
Table 45. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 46. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
Table 47. GlaxoSmithKline Recent Development
Table 48. AstraZeneca Company Information
Table 49. AstraZeneca Business Overview
Table 50. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 51. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
Table 52. AstraZeneca Recent Development
Table 53. Boehringer Ingelheim Company Information
Table 54. Boehringer Ingelheim Business Overview
Table 55. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 56. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
Table 57. Boehringer Ingelheim Recent Development
Table 58. Teva Pharmaceutical Industries Company Information
Table 59. Teva Pharmaceutical Industries Business Overview
Table 60. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 61. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
Table 62. Teva Pharmaceutical Industries Recent Development
Table 63. Takeda Company Information
Table 64. Takeda Business Overview
Table 65. Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 66. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
Table 67. Takeda Recent Development
Table 68. Baxter Company Information
Table 69. Baxter Business Overview
Table 70. Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 71. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
Table 72. Baxter Recent Development
Table 73. Grifols Company Information
Table 74. Grifols Business Overview
Table 75. Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 76. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
Table 77. Grifols Recent Development
Table 78. CSL Behring Company Information
Table 79. CSL Behring Business Overview
Table 80. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 81. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
Table 82. CSL Behring Recent Development
Table 83. Kamada Ltd Company Information
Table 84. Kamada Ltd Business Overview
Table 85. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 86. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
Table 87. Kamada Ltd Recent Development
Table 88. Chiesi Pharmaceuticals Company Information
Table 89. Chiesi Pharmaceuticals Business Overview
Table 90. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
Table 91. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
Table 92. Chiesi Pharmaceuticals Recent Development
Table 93. Kedrion Group Company Information
Table 94. Kedrion Group Business Overview
Table 95. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
Table 96. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
Table 97. Kedrion Group Recent Development
Table 98. Vertex Pharmaceuticals Company Information
Table 99. Vertex Pharmaceuticals Business Overview
Table 100. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
Table 101. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
Table 102. Vertex Pharmaceuticals Recent Development
Table 103. ProMetic Life Sciences Company Information
Table 104. ProMetic Life Sciences Business Overview
Table 105. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
Table 106. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
Table 107. ProMetic Life Sciences Recent Development
Table 108. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2019-2024) & (US$ Million)
Table 109. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2019-2024) & (US$ Million)
Table 110. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 111. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2019-2024) & (US$ Million)
Table 112. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2025-2030) & (US$ Million)
Table 113. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2019-2024) & (US$ Million)
Table 114. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2019-2024) & (US$ Million)
Table 115. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 116. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2019-2024) & (US$ Million)
Table 117. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2025-2030) & (US$ Million)
Table 118. China Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2019-2024) & (US$ Million)
Table 119. China Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2019-2024) & (US$ Million)
Table 120. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2019-2024) & (US$ Million)
Table 121. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2019-2024) & (US$ Million)
Table 122. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 123. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2019-2024) & (US$ Million)
Table 124. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2025-2030) & (US$ Million)
Table 125. MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2019-2024) & (US$ Million)
Table 126. MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2019-2024) & (US$ Million)
Table 127. MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 128. MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2019-2024) & (US$ Million)
Table 129. MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2025-2030) & (US$ Million)
Table 130. Research Programs/Design for This Report
Table 131. Authors List of This Report
Table 132. Secondary Sources
Table 133. Primary Sources
List of Figures
Figure 1. Alpha 1 Antitrypsin Deficiency Treatment Product Picture
Figure 2. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Indication (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Share 2019 VS 2023 VS 2030
Figure 4. Augmentation Therapy Picture
Figure 5. Cystic Fibrosis(CF) Picture
Figure 6. Non-CF Bronchiectasis(NCFB) Picture
Figure 7. Diabetes Picture
Figure 8. Other Picture
Figure 9. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by End Users (US$ Million), 2019 VS 2023 VS 2030
Figure 10. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Share 2019 VS 2023 VS 2030
Figure 11. COPD Picture
Figure 12. Cystic Fibrosis(CF) Picture
Figure 13. Non-CF Bronchiectasis(NCFB) Picture
Figure 14. Diabetes Picture
Figure 15. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (US$ Million) & (2019-2030)
Figure 16. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region: 2019 VS 2023 VS 2030
Figure 18. Global Alpha 1 Antitrypsin Deficiency Treatment Players Revenue Share Top 10 and Top 5 in 2023
Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 20. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2019 VS 2023 VS 2030) & (US$ Million)
Figure 21. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share 2019 VS 2023 VS 2030
Figure 22. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2019-2030)
Figure 23. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2019 VS 2023 VS 2030) & (US$ Million)
Figure 24. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2019 VS 2023 VS 2030)
Figure 25. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2019-2030)
Figure 26. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 27. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2025-2030) & (US$ Million)
Figure 28. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Type (2019-2030)
Figure 29. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2025-2030) & (US$ Million)
Figure 30. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Application (2019-2030)
Figure 31. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Country (2019-2030)
Figure 32. United States Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 33. Canada Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 34. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 35. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2025-2030) & (US$ Million)
Figure 36. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Type (2019-2030)
Figure 37. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2025-2030) & (US$ Million)
Figure 38. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Application (2019-2030)
Figure 39. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Country (2019-2030)
Figure 40. Germany Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 41. France Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 42. U.K. Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. Italy Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 44. Russia Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 45. Nordic Countries Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 46. China Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 47. China Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2025-2030) & (US$ Million)
Figure 48. China Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Type (2019-2030)
Figure 49. China Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2025-2030) & (US$ Million)
Figure 50. China Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Application (2019-2030)
Figure 51. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 52. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2025-2030) & (US$ Million)
Figure 53. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Type (2019-2030)
Figure 54. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2025-2030) & (US$ Million)
Figure 55. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Application (2019-2030)
Figure 56. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Country (2019-2030)
Figure 57. Japan Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 58. South Korea Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 59. India Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 60. Australia Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 61. China Taiwan Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 62. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 63. MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 64. MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2025-2030) & (US$ Million)
Figure 65. MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Type (2019-2030)
Figure 66. MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2025-2030) & (US$ Million)
Figure 67. MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Application (2019-2030)
Figure 68. MEALA Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Country (2019-2030)
Figure 69. Mexico Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 70. South Korea Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 71. Brazil Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 72. Israel Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 73. Argentina Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 74. Colombia Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 75. Turkey Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 76. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 77. UAE Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 78. Years Considered
Figure 79. Research Process
Figure 80. Key Executives Interviewed
